Xeris Biopharma Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Xeris Biopharma Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $49.59M | Mar 11, 2022 |
| FY2021 | Dec 31, 2020 | $20.44M | Mar 11, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $291.85M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $203.07M | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | $40.64M | May 9, 2024 |
| FY2025 | Dec 31, 2023 | $163.91M | Mar 2, 2026 |
| FY2023 | Jun 30, 2023 | $38.01M | Aug 8, 2023 |
| FY2024 | Mar 31, 2023 | $33.20M | May 9, 2024 |
| FY2024 | Dec 31, 2022 | $110.25M | Mar 6, 2025 |
| FY2023 | Jun 30, 2022 | $25.31M | Aug 8, 2023 |
| FY2023 | Mar 31, 2022 | $22.07M | May 9, 2023 |
| FY2023 | Dec 31, 2021 | $49.59M | Mar 6, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $554.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($54.84M) | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | ($18.98M) | May 9, 2024 |
| FY2025 | Dec 31, 2023 | ($62.26M) | Mar 2, 2026 |
| FY2023 | Jun 30, 2023 | ($19.84M) | Aug 8, 2023 |
| FY2024 | Mar 31, 2023 | ($16.83M) | May 9, 2024 |
| FY2024 | Dec 31, 2022 | ($94.66M) | Mar 6, 2025 |
| FY2023 | Jun 30, 2022 | ($26.19M) | Aug 8, 2023 |
| FY2023 | Mar 31, 2022 | ($33.71M) | Aug 8, 2023 |
| FY2023 | Dec 31, 2021 | ($122.73M) | Mar 6, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($33.65M) | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | ($14.25M) | May 9, 2024 |
| FY2025 | Dec 31, 2023 | ($44.01M) | Mar 2, 2026 |
| FY2023 | Jun 30, 2023 | ($15.98M) | Aug 8, 2023 |
| FY2024 | Mar 31, 2023 | ($13.28M) | May 9, 2024 |
| FY2024 | Dec 31, 2022 | ($81.94M) | Mar 6, 2025 |
| FY2023 | Jun 30, 2022 | ($18.92M) | Aug 8, 2023 |
| FY2023 | Mar 31, 2022 | ($29.07M) | May 9, 2023 |
| FY2023 | Dec 31, 2021 | ($115.16M) | Mar 6, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $383.53M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $323.06M | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | $336.62M | May 9, 2024 |
| FY2024 | Dec 31, 2023 | $322.60M | Mar 6, 2025 |
| FY2023 | Jun 30, 2023 | $328.78M | Aug 8, 2023 |
| FY2023 | Mar 31, 2023 | $321.36M | May 9, 2023 |
| FY2023 | Dec 31, 2022 | $344.52M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $304.36M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $159.15M | Mar 11, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $369.84M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $352.68M | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | $345.79M | May 9, 2024 |
| FY2024 | Dec 31, 2023 | $329.38M | Mar 6, 2025 |
| FY2023 | Jun 30, 2023 | $315.14M | Aug 8, 2023 |
| FY2023 | Mar 31, 2023 | $291.31M | May 9, 2023 |
| FY2023 | Dec 31, 2022 | $299.34M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $209.13M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $125.39M | Mar 11, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.69M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($29.62M) | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | ($9.18M) | May 9, 2024 |
| FY2025 | Dec 31, 2023 | ($6.78M) | Mar 2, 2026 |
| FY2023 | Jun 30, 2023 | $13.64M | Aug 8, 2023 |
| FY2024 | Mar 31, 2023 | $30.05M | May 9, 2024 |
| FY2025 | Dec 31, 2022 | $45.19M | Mar 2, 2026 |
| FY2023 | Jun 30, 2022 | $73.94M | Aug 8, 2023 |
| FY2023 | Mar 31, 2022 | $96.46M | Aug 8, 2023 |
| FY2024 | Dec 31, 2021 | $95.23M | Mar 6, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | 0 | May 9, 2024 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2023 | Jun 30, 2023 | 0 | Aug 8, 2023 |
| FY2024 | Mar 31, 2023 | 0 | May 9, 2024 |
| FY2024 | Dec 31, 2022 | 0 | Mar 6, 2025 |
| FY2023 | Jun 30, 2022 | 0 | Aug 8, 2023 |
| FY2023 | Mar 31, 2022 | 0 | May 9, 2023 |
| FY2023 | Dec 31, 2021 | (1) | Mar 6, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | 0 | May 9, 2024 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2023 | Jun 30, 2023 | 0 | Aug 8, 2023 |
| FY2024 | Mar 31, 2023 | 0 | May 9, 2024 |
| FY2024 | Dec 31, 2022 | 0 | Mar 6, 2025 |
| FY2023 | Jun 30, 2022 | 0 | Aug 8, 2023 |
| FY2023 | Mar 31, 2022 | 0 | May 9, 2023 |
| FY2023 | Dec 31, 2021 | (1) | Mar 6, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.04M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $71.62M | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | $62.69M | May 9, 2024 |
| FY2025 | Dec 31, 2023 | $67.45M | Mar 2, 2026 |
| FY2023 | Jun 30, 2023 | $46.17M | Aug 8, 2023 |
| FY2024 | Mar 31, 2023 | $50.98M | May 9, 2024 |
| FY2023 | Dec 31, 2022 | $121.97M | Mar 6, 2024 |
| FY2023 | Jun 30, 2022 | $95.34M | Aug 8, 2023 |
| FY2023 | Mar 31, 2022 | $103.77M | May 9, 2023 |
| FY2022 | Dec 31, 2021 | $67.27M | Mar 8, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $232.11M | Mar 2, 2026 |
| FY2024 | Mar 31, 2024 | $229.67M | May 9, 2024 |
| FY2024 | Dec 31, 2023 | $190.93M | Mar 6, 2025 |
| FY2023 | Jun 30, 2023 | $188.18M | Aug 8, 2023 |
| FY2023 | Mar 31, 2023 | $187.62M | May 9, 2023 |
| FY2023 | Dec 31, 2022 | $187.08M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $88.07M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $87.02M | Mar 11, 2022 |